

STIC Search Report

Biotech-Chem Library

STIC Database Tracking Number: 173154

TO: Robert J Balls
Location: 4d78 / 4c70
Art Unit: 1625
Tuesday, January 31, 2006

Case Serial Number: 10/826136

From: Noble Jarrell
Location: Biotech-Chem Library
Rem 1B71
Phone: 272-2556

Noble.jarrell@uspto.gov

Search Notes

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: James Balls Examiner #: 82049 Date: 31 Jan 2006
Art Unit: 625 Phone Number: 2- Serial Number: 10/82049-136
Location (Bldg/Room#): 4D78 (Mailbox #): 4670 Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: _____

Inventors (please provide full names): Robert Hofgen

Earliest Priority Date: _____

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.

STAFF USE ONLY

Searcher: NOBLE

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: 1/31/06

Date Completed: 1/31/06

Searcher Prep & Review Time: W

Online Time: 71

Type of Search

____ NA Sequence (#)

____ AA Sequence (#)

3 Structure (#)

✓ Bibliographic

____ Litigation

____ Fulltext

____ Other

Vendors and cost where applicable

✓ STN _____ Dialog

____ Questel/Orbit _____ Lexis/Nexis

____ Westlaw _____ WWW/Internet

____ In-house sequence systems

____ Commercial _____ Oligomer _____ Score/Length
____ Interference _____ SPDI _____ Encode/Transl
____ Other (specify)

=> b reg

FILE 'REGISTRY' ENTERED AT 13:08:09 ON 31 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 30 JAN 2006 HIGHEST RN 873057-98-8

DICTIONARY FILE UPDATES: 30 JAN 2006 HIGHEST RN 873057-98-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2005

Please note that search-term pricing does apply when conducting SmartSELECT searches.

```
*****
*
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
*
*****
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:


<http://www.cas.org/ONLINE/UG/regprops.html>

=> d que sta 117

L15 STR

N~O
@10 11

N—Ak
@23 24



VAR G1=N/10

VAR G2=C/N/10

VAR G3=NH/23

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 21

CONNECT IS E1 RC AT 22

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L17 52 SEA FILE=REGISTRY SSS FUL L15


100.0% PROCESSED 55 ITERATIONS

52 ANSWERS

SEARCH TIME: 00.00.01

=> d que sta l25

L23 STR



VAR G1=N/10

VAR G2=C/N/10

VAR G4=7/8

VAR G5=15/16/17

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 21

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L25 98 SEA FILE=REGISTRY SSS FUL L23


100.0% PROCESSED 199771 ITERATIONS

98 ANSWERS

SEARCH TIME: 00.00.13

=> d que sta l37

L23 STR



VAR G1=N/10

VAR G2=C/N/10

VAR G4=7/8

VAR G5=15/16/17

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 21

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:


RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24

STEREO ATTRIBUTES: NONE

L25 98 SEA FILE=REGISTRY SSS FUL L23

L34 STR



VAR G1=N/10

VAR G4=7/8

NODE ATTRIBUTES:

CONNECT IS E1 RC AT 21

DEFAULT MLEVEL IS ATOM

GGCAT IS UNS AT 27

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 18

STEREO ATTRIBUTES: NONE

L36 101 SEA FILE=REGISTRY SSS FUL L34

L37 3 SEA FILE=REGISTRY ABB=ON PLU=ON L36 NOT L25

=> b hcap

FILE 'HCAPLUS' ENTERED AT 13:08:46 ON 31 JAN 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 31 Jan 2006 VOL 144 ISS 6

FILE LAST UPDATED: 30 Jan 2006 (20060130/ED)

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> => d all hitstr l41 1-2

L41 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:1037098 HCAPLUS

DN 143:347150

ED Entered STN: 28 Sep 2005

TI Preparation of pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors

IN Salom, Barbara; D'Anello, Matteo; Brasca, Maria Gabriella; Giordano, Patrizia; Martina, Katia; Angelucci, Francesco; Brookfield, Frederick

Arthur; Trigg, William John; Boyd, Edward Andrew; Larard, Jonathan Anthony
 PA Pharmacia Italia S.p.A., Italy
 SO PCT Int. Appl., 102 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 IC C07D-0471/04; A61K-0031/437
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1, 63



FAN.CNT 4

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2005063746	A1	20050714	2004WO-XC14674	20041223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO2005063746	A1	20050714	2004WO-EP14674	20041223
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRAI	2003GB-0030043	A	20031224		
	2004WO-EP14674	A	20041223		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005063746	IC	C07D-0471/04; A61K-0031/437
	IPCI	C07D0471-04 [ICM]; A61K0031-437 [ICS]
	ECLA	C07D471/04+221B+209B
WO2005063746	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]
	ECLA	C07D471/04+221B+209B

GI



- AB The title compds. [I; R = Ra, CORa, CONRaRb, SO₂Ra, CO₂Ra; R₁ = NRcRd, ORc; Ra, Rb, Rc and Rd = H, alkyl, cycloalkyl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compns. comprising them, as well as combinatorial libraries of compds. I, are disclosed. Preparation of compds. I is described in eleven synthetic examples. E.g., a multi-step synthesis of II, starting from 5-nitro-1H-pyrrolo[2,3-b]pyridine-3-carboxylic acid and isoamylamine-bearing resin, was given. The compds. I or compns. comprising them may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders. Also disclosed is a process under SPS conditions for preparing the compds. I and chemical libraries comprising a plurality of them. This is a Part IV of I-IV series.
- ST pyrrolopyridine prepn protein kinase inhibitor antitumor antiproliferative antiviral; Alzheimer disease pyrrolopyridine prepn; neurodegenerative disorder pyrrolopyridine prepn; combinatorial library pyrrolopyridine prepn protein kinase inhibitor
- IT Sarcoma
(Kaposi's, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Antiarteriosclerotics
(antiatherosclerotics, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Prostate gland, disease
(benign hyperplasia, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Hyperplasia
(benign prostatic, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Nervous system, disease
(degeneration, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Lung, disease
(fibrosis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Thyroid gland, neoplasm
(follicle cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Chemotherapy
Radiotherapy
(for augmentation of; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Inflammation

Kidney, disease
 (glomerulonephritis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Transplant and Transplantation
 (host-vs.-graft reaction; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
 (lymphoid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
 (mesenchymal, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
 (metastasis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Endocrine system, neoplasm
 Neoplasm
 (multiple endocrine neoplasia, treating familial adenomatosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
 (myeloid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Mesenchyme
 (neoplasm, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, neoplasm
 (neurofibromatosis type 1, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Bone, neoplasm
 Sarcoma
 (osteosarcoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Digestive tract, neoplasm
 (polyposis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Angiogenesis
 Angiogenesis inhibitors
 Anti-Alzheimer's agents
 Antitumor agents
 Antiviral agents
 Cell proliferation
 Combination chemotherapy
 Combinatorial chemistry
 Combinatorial library
 Human
 Immunomodulators
 Immunosuppressants
 Nervous system agents
 Solid phase synthesis
 Transplant rejection
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Fibrosis
 (pulmonary, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Artery, disease
 (restenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Testis, neoplasm
 (seminoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Blood vessel
 (smooth muscle, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Carcinoma
 (squamous cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as

kinase inhibitors)

IT Artery, disease
(stenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Carcinoma
(teratocarcinoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Alopecia
(treating or preventing radiotherapy-induced or chemotherapy-induced alopecia; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Atherosclerosis
(treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Alzheimer's disease

Antiarthritics

Arthritis

Autoimmune disease

Carcinoma

Melanoma

Nervous system, neoplasm

Psoriasis
(treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Infection
(viral, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Skin, disease
(xanthoma, treating keratoxanthoma; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Skin, disease
(xeroderma pigmentosum, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 372092-80-3, Protein kinase

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865839-17-4P 865839-18-5P 865839-19-6P 865839-20-9P 865839-21-0P
865839-22-1P 865839-23-2P 865839-24-3P 865839-25-4P 865839-26-5P
865839-27-6P 865839-28-7P 865839-29-8P 865839-30-1P 865839-31-2P
865839-32-3P 865839-33-4P 865839-34-5P 865839-35-6P 865839-36-7P
865839-37-8P 865839-38-9P 865839-39-0P 865839-40-3P 865839-41-4P
865839-42-5P 865839-43-6P 865839-44-7P 865839-45-8P 865839-46-9P
865839-47-0P 865839-48-1P 865839-51-6P 865839-52-7P 865839-53-8P
865839-54-9P 865839-55-0P 865839-56-1P 865839-57-2P 865839-58-3P
865839-59-4P 865839-60-7P 865839-61-8P 865839-62-9P 865839-63-0P
865839-64-1P 865839-65-2P 865839-66-3P 865839-67-4P 865839-68-5P
865839-69-6P 865839-70-9P 865839-71-0P 865839-72-1P 865839-73-2P
865839-74-3P 865839-75-4P 865839-76-5P 865839-77-6P 865839-78-7P
865839-79-8P 865839-80-1P 865839-81-2P 865839-82-3P 865839-83-4P
865839-84-5P 865839-85-6P 865839-86-7P 865839-87-8P 865839-88-9P
865839-89-0P 865839-91-4P 865839-92-5P 865839-93-6P 865839-94-7P
865839-95-8P 865839-97-0P 865840-00-2P 865840-03-5P 865840-04-6P
865840-05-7P 865840-08-0P 865840-11-5P 865840-12-6P 865840-13-7P
865840-14-8P 865840-15-9P 865840-16-0P 865840-17-1P 865840-18-2P
865840-19-3P 865840-20-6P 865840-21-7P 865840-22-8P 865840-23-9P
865840-24-0P 865840-25-1P 865840-26-2P 865840-27-3P 865840-28-4P
865840-29-5P 865840-30-8P 865840-31-9P 865840-32-0P 865840-33-1P
865840-34-2P 865840-35-3P 865840-36-4P 865840-38-6P 865840-39-7P
865840-40-0P 865840-41-1P 865840-42-2P 865840-43-3P 865840-44-4P
865840-45-5P 865840-46-6P 865840-47-7P 865840-48-8P 865840-49-9P
865840-50-2P 865840-51-3P 865840-52-4P 865840-53-5P 865840-54-6P
865840-55-7P 865840-56-8P 865840-57-9P 865840-58-0P 865840-59-1P
865840-60-4P 865840-61-5P 865840-62-6P 865840-63-7P 865840-64-8P
865840-65-9P 865840-66-0P 865840-67-1P 865840-68-2P 865840-69-3P
865840-70-6P 865840-71-7P 865840-72-8P 865840-73-9P 865840-74-0P

865840-75-1P	865840-76-2P	865840-78-4P	865840-79-5P	865840-80-8P
865840-81-9P	865840-82-0P	865840-83-1P	865840-84-2P	865840-85-3P
865840-86-4P	865840-87-5P	865840-88-6P	865840-89-7P	865840-90-0P
865840-91-1P	865840-92-2P	865840-93-3P	865840-94-4P	865840-95-5P
865840-96-6P	865840-97-7P	865840-98-8P	865840-99-9P	865841-00-5P
865841-01-6P	865841-02-7P	865841-03-8P	865841-04-9P	865841-05-0P
865841-06-1P	865841-07-2P	865841-08-3P	865841-09-4P	865841-10-7P
865841-11-8P	865841-12-9P	865841-14-1P	865841-15-2P	865841-16-3P
865841-17-4P	865841-18-5P	865841-19-6P	865841-20-9P	865841-21-0P
865841-22-1P	865841-23-2P	865841-24-3P	865841-25-4P	865841-26-5P
865841-27-6P	865841-28-7P	865841-29-8P	865841-30-1P	865841-31-2P
865841-32-3P	865841-33-4P	865841-34-5P	865841-35-6P	865841-36-7P
865841-37-8P	865841-38-9P	865841-39-0P	865841-40-3P	865841-41-4P
865841-42-5P	865841-43-6P	865841-44-7P	865841-45-8P	865841-46-9P
865841-48-1P	865841-49-2P	865841-50-5P	865841-51-6P	865841-52-7P
865841-53-8P	865841-54-9P	865841-55-0P	865841-56-1P	865841-57-2P
865841-58-3P	865841-59-4P	865841-60-7P	865841-61-8P	865841-62-9P
865841-63-0P	865841-64-1P	865841-65-2P	865841-66-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT	865841-67-4P	865841-68-5P	865841-69-6P	865841-70-9P	865841-71-0P
	865841-72-1P	865841-73-2P	865841-74-3P	865841-75-4P	865841-76-5P
	865841-77-6P	865841-78-7P	865841-79-8P	865841-80-1P	865841-81-2P
	865841-82-3P	865841-83-4P	865841-84-5P	865841-86-7P	865841-87-8P
	865841-88-9P	865841-89-0P	865841-90-3P	865841-91-4P	865841-92-5P
	865841-93-6P	865841-94-7P	865841-95-8P	865841-96-9P	865841-97-0P
	865841-98-1P	865841-99-2P	865842-00-8P	865842-01-9P	865842-02-0P
	865842-03-1P	865842-04-2P	865842-05-3P	865842-06-4P	865842-07-5P
	865842-08-6P	865842-09-7P	865842-10-0P	865842-11-1P	865842-12-2P
	865842-13-3P	865842-14-4P	865842-15-5P	865842-16-6P	865842-17-7P
	865842-18-8P	865842-19-9P	865842-20-2P	865842-21-3P	865842-22-4P
	865842-23-5P	865842-24-6P	865842-25-7P	865842-26-8P	865842-27-9P
	865842-28-0P	865842-29-1P	865842-30-4P	865842-31-5P	865842-32-6P
	865842-33-7P	865842-34-8P	865842-35-9P	865842-36-0P	865842-37-1P
	865842-38-2P	865842-39-3P	865842-40-6P	865842-41-7P	865842-42-8P
	865842-43-9P	865842-44-0P	865842-45-1P	865842-46-2P	865842-47-3P
	865842-48-4P	865842-49-5P	865842-50-8P	865842-51-9P	865842-52-0P
	865842-53-1P	865842-54-2P	865842-55-3P	865842-56-4P	865842-57-5P
	865842-58-6P	865842-59-7P	865842-60-0P	865842-61-1P	865842-62-2P
	865842-63-3P	865842-64-4P	865842-65-5P	865842-66-6P	865842-67-7P
	865842-68-8P	865842-69-9P	865842-70-2P	865842-71-3P	865842-72-4P
	865842-73-5P	865842-74-6P	865842-75-7P	865842-76-8P	865842-77-9P
	865842-78-0P	865842-79-1P	865842-80-4P	865842-81-5P	865842-82-6P
	865842-83-7P	865842-84-8P	865842-85-9P	865842-86-0P	865842-87-1P
	865842-88-2P	865842-89-3P	865842-90-6P	865842-91-7P	865842-92-8P
	865842-93-9P	865842-94-0P	865842-95-1P	865842-96-2P	865842-97-3P
	865842-98-4P	865842-99-5P	865843-00-1P	865843-01-2P	865843-02-3P
	865843-03-4P	865843-04-5P	865843-05-6P	865843-06-7P	865843-07-8P
	865843-08-9P	865843-09-0P	865843-10-3P	865843-11-4P	865843-12-5P
	865843-13-6P	865843-14-7P	865843-15-8P	865843-16-9P	865843-17-0P
	865843-18-1P	865843-19-2P	865843-20-5P	865843-21-6P	865843-22-7P
	865843-23-8P	865843-25-0P	865843-26-1P	865843-27-2P	865843-28-3P
	865843-29-4P	865843-30-7P	865843-31-8P	865843-32-9P	865843-33-0P
	865843-34-1P	865843-35-2P	865843-36-3P	865843-37-4P	865843-38-5P
	865843-39-6P	865843-40-9P	865843-41-0P	865843-42-1P	865843-43-2P
	865843-44-3P	865843-45-4P	865843-46-5P	865843-47-6P	865843-48-7P
	865843-49-8P	865843-50-1P	865843-51-2P	865843-52-3P	865843-53-4P
	865843-54-5P	865843-55-6P	865843-56-7P	865843-57-8P	865843-58-9P
	865843-59-0P	865843-60-3P	865843-61-4P	865843-62-5P	865843-63-6P
	865843-64-7P	865843-65-8P	865843-66-9P	865843-67-0P	865843-68-1P
	865843-69-2P	865843-70-5P	865843-71-6P	865843-72-7P	865843-73-8P
	865843-74-9P	865843-75-0P	865843-76-1P	865843-77-2P	865843-78-3P
	865843-79-4P	865843-80-7P	865843-81-8P	865843-82-9P	865843-83-0P
	865843-84-1P	865843-85-2P	865843-86-3P	865843-87-4P	865843-88-5P

865843-89-6P 865843-90-9P 865843-91-0P 865843-92-1P 865843-93-2P
 865843-94-3P 865843-95-4P 865843-96-5P 865843-97-6P 865843-98-7P
 865843-99-8P 865844-00-4P 865844-02-6P 865844-03-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT	865844-04-8P	865844-05-9P	865844-06-0P	865844-07-1P	865844-08-2P
	865844-09-3P	865844-10-6P	865844-11-7P	865844-12-8P	865844-13-9P
	865844-14-0P	865844-15-1P	865844-16-2P	865844-17-3P	865844-18-4P
	865844-19-5P	865844-20-8P	865844-21-9P	865844-22-0P	865844-23-1P
	865844-24-2P	865844-25-3P	865844-26-4P	865844-27-5P	865844-28-6P
	865844-29-7P	865844-30-0P	865844-31-1P	865844-32-2P	865844-33-3P
	865844-34-4P	865844-35-5P	865844-36-6P	865844-37-7P	865844-38-8P
	865844-39-9P	865844-40-2P	865844-41-3P	865844-42-4P	865844-43-5P
	865844-44-6P	865844-45-7P	865844-46-8P	865844-47-9P	865844-48-0P
	865844-49-1P	865844-50-4P	865844-51-5P	865844-52-6P	865844-53-7P
	865844-54-8P	865844-55-9P	865844-56-0P	865844-57-1P	865844-58-2P
	865844-59-3P	865844-60-6P	865844-61-7P	865844-62-8P	865844-63-9P
	865844-64-0P	865844-65-1P	865844-66-2P	865844-67-3P	865844-68-4P
	865844-69-5P	865844-70-8P	865844-71-9P	865844-72-0P	865844-73-1P
	865844-74-2P	865844-75-3P	865844-76-4P	865844-77-5P	865844-78-6P
	865844-79-7P	865844-80-0P	865844-81-1P	865844-82-2P	865844-83-3P
	865844-84-4P	865844-85-5P	865844-86-6P	865844-87-7P	865844-88-8P
	865844-89-9P	865844-90-2P	865844-91-3P	865844-92-4P	865844-93-5P
	865844-94-6P	865844-95-7P	865844-96-8P	865844-97-9P	865844-98-0P
	865844-99-1P	865845-00-7P	865845-01-8P	865845-02-9P	865845-03-0P
	865845-04-1P	865845-05-2P	865845-06-3P	865845-07-4P	865845-08-5P
	865845-09-6P	865845-10-9P	865845-11-0P	865845-12-1P	865845-13-2P
	865845-14-3P	865845-15-4P	865845-16-5P	865845-17-6P	865845-18-7P
	865845-19-8P	865845-20-1P	865845-21-2P	865845-22-3P	865845-23-4P
	865845-24-5P	865845-25-6P	865845-26-7P	865845-27-8P	865845-28-9P
	865845-29-0P	865845-30-3P	865845-31-4P	865845-32-5P	865845-33-6P
	865845-34-7P	865845-35-8P	865845-36-9P	865845-37-0P	865845-38-1P
	865845-39-2P	865845-40-5P	865845-41-6P	865845-42-7P	865845-43-8P
	865845-44-9P	865845-45-0P	865845-46-1P	865845-47-2P	865845-48-3P
	865845-49-4P	865845-50-7P	865845-51-8P	865845-52-9P	865845-53-0P
	865845-54-1P	865845-55-2P	865845-56-3P	865845-57-4P	865845-58-5P
	865845-59-6P	865845-60-9P	865845-61-0P	865845-62-1P	865845-63-2P
	865845-64-3P	865845-65-4P	865845-66-5P	865845-67-6P	865845-68-7P
	865845-69-8P	865845-70-1P	865845-71-2P	865845-72-3P	865845-73-4P
	865845-74-5P	865845-75-6P	865845-76-7P	865845-77-8P	865845-78-9P
	865845-79-0P	865845-80-3P	865845-81-4P	865845-82-5P	865845-83-6P
	865845-84-7P	865845-85-8P	865845-86-9P	865845-87-0P	865845-88-1P
	865845-89-2P	865845-90-5P	865845-91-6P	865845-92-7P	865845-93-8P
	865845-94-9P	865845-95-0P	865845-96-1P	865845-97-2P	865845-98-3P
	865845-99-4P	865846-00-0P	865846-01-1P	865846-02-2P	865846-03-3P
	865846-04-4P	865846-05-5P	865846-06-6P	865846-07-7P	865846-08-8P
	865846-09-9P	865846-10-2P	865846-11-3P	865846-12-4P	865846-13-5P
	865846-14-6P	865846-15-7P	865846-16-8P	865846-17-9P	865846-18-0P
	865846-19-1P	865846-20-4P	865846-21-5P	865846-22-6P	865846-23-7P
	865846-24-8P	865846-25-9P	865846-26-0P	865846-27-1P	865846-28-2P
	865846-29-3P	865846-30-6P	865846-31-7P	865846-32-8P	865846-33-9P
	865846-34-0P	865846-35-1P	865846-36-2P	865846-37-3P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT	865846-38-4P	865846-39-5P	865846-40-8P	865846-41-9P	865846-42-0P
	865846-43-1P	865846-44-2P	865846-45-3P	865846-46-4P	865846-47-5P
	865846-48-6P	865846-49-7P	865846-50-0P	865846-51-1P	865846-52-2P
	865846-53-3P	865846-54-4P	865846-55-5P	865846-56-6P	865846-57-7P
	865846-58-8P	865846-59-9P	865846-60-2P	865846-61-3P	865846-62-4P
	865846-63-5P	865846-64-6P	865846-65-7P	865846-66-8P	865846-67-9P
	865846-68-0P	865846-69-1P	865846-70-4P	865846-71-5P	865846-72-6P
	865846-73-7P	865846-74-8P	865846-75-9P	865846-76-0P	865846-77-1P

865846-78-2P	865846-79-3P	865846-80-6P	865846-81-7P	865846-82-8P
865846-83-9P	865846-84-0P	865846-85-1P	865846-86-2P	865846-87-3P
865846-88-4P	865846-89-5P	865846-90-8P	865846-91-9P	865846-92-0P
865846-93-1P	865846-94-2P	865846-95-3P	865846-96-4P	865846-97-5P
865846-98-6P	865846-99-7P	865847-00-3P	865847-01-4P	865847-02-5P
865847-03-6P	865847-04-7P	865847-05-8P	865847-06-9P	865847-07-0P
865847-08-1P	865847-09-2P	865847-10-5P	865847-11-6P	865847-12-7P
865847-13-8P	865847-14-9P	865847-15-0P	865847-16-1P	865847-17-2P
865847-18-3P	865847-19-4P	865847-20-7P	865847-21-8P	865847-22-9P
865847-23-0P	865847-24-1P	865847-25-2P	865847-26-3P	865847-27-4P
865847-28-5P	865847-29-6P	865847-30-9P	865847-31-0P	865847-32-1P
865847-33-2P	865847-34-3P	865847-35-4P	865847-36-5P	865847-37-6P
865847-38-7P	865847-39-8P	865847-40-1P	865847-41-2P	865847-42-3P
865847-43-4P	865847-44-5P	865847-45-6P	865847-46-7P	865847-47-8P
865847-48-9P	865847-49-0P	865847-50-3P	865847-51-4P	865847-52-5P
865847-53-6P	865847-54-7P	865847-55-8P	865847-56-9P	865847-57-0P
865847-58-1P	865847-59-2P	865847-60-5P	865847-61-6P	865847-62-7P
865847-63-8P	865847-64-9P	865847-65-0P	865847-66-1P	865847-67-2P
865847-68-3P	865847-69-4P	865847-70-7P	865847-71-8P	865847-72-9P
865847-73-0P	865847-74-1P	865847-75-2P	865847-76-3P	865847-77-4P
865847-78-5P	865847-79-6P	865847-80-9P	865847-81-0P	865847-82-1P
865847-83-2P	865847-84-3P	865847-85-4P	865847-86-5P	865847-87-6P
865847-88-7P	865847-89-8P	865847-90-1P	865847-91-2P	865847-92-3P
865847-93-4P	865847-94-5P	865847-95-6P	865847-96-7P	865847-97-8P
865847-98-9P	865847-99-0P	865848-00-6P	865848-01-7P	865848-02-8P
865848-03-9P	865848-04-0P	865848-05-1P	865848-06-2P	865848-07-3P
865848-08-4P	865848-09-5P	865848-10-8P	865848-11-9P	865848-12-0P
865848-13-1P	865848-14-2P	865848-15-3P	865848-16-4P	865848-17-5P
865848-18-6P	865848-19-7P	865848-20-0P	865848-21-1P	865848-22-2P
865848-23-3P	865848-24-4P	865848-25-5P	865848-26-6P	865848-27-7P
865848-28-8P	865848-29-9P	865848-30-2P	865848-31-3P	865848-32-4P
865848-33-5P	865848-34-6P	865848-35-7P	865848-36-8P	865848-37-9P
865848-40-4P	865848-41-5P	865848-44-8P	865848-45-9P	865848-46-0P
865848-47-1P	865848-48-2P	865848-49-3P	865848-50-6P	865848-51-7P
865848-52-8P	865848-53-9P	865848-54-0P	865848-55-1P	865848-56-2P
865848-57-3P	865848-58-4P	865848-59-5P	865848-60-8P	865848-61-9P
865848-62-0P	865848-63-1P	865848-64-2P	865848-65-3P	865848-66-4P
865848-67-5P	865848-68-6P	865848-69-7P	865848-70-0P	865848-71-1P
865848-72-2P	865848-73-3P	865848-74-4P	865848-75-5P	

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT	865848-76-6P	865848-77-7P	865848-78-8P	865848-79-9P	865848-80-2P
	865848-81-3P	865848-82-4P	865848-83-5P	865848-84-6P	865848-85-7P
	865848-86-8P	865848-87-9P	865848-88-0P	865848-89-1P	865848-90-4P
	865848-91-5P	865848-92-6P	865848-93-7P	865848-94-8P	865848-95-9P
	865848-96-0P	865848-97-1P	865848-98-2P	865848-99-3P	865849-00-9P
	865849-01-0P	865849-02-1P	865849-03-2P	865849-04-3P	865849-05-4P
	865849-06-5P	865849-07-6P	865849-08-7P	865849-09-8P	865849-10-1P
	865849-11-2P	865849-12-3P	865849-13-4P	865849-14-5P	865849-15-6P
	865849-16-7P	865849-17-8P	865849-18-9P	865849-19-0P	865849-20-3P
	865849-21-4P	865849-22-5P	865849-23-6P	865849-24-7P	865849-25-8P
	865849-26-9P	865849-27-0P	865849-28-1P	865849-29-2P	865849-30-5P
	865849-31-6P	865849-32-7P	865849-33-8P	865849-34-9P	865849-35-0P
	865849-36-1P	865849-37-2P	865849-38-3P	865849-39-4P	865849-40-7P
	865849-41-8P	865849-42-9P	865849-43-0P	865849-44-1P	865849-45-2P
	865849-46-3P	865849-47-4P	865849-48-5P	865849-49-6P	865849-50-9P
	865849-51-0P	865849-52-1P	865849-53-2P	865849-54-3P	865849-55-4P
	865849-56-5P	865849-57-6P	865849-58-7P	865849-59-8P	865849-60-1P
	865849-61-2P	865849-62-3P	865849-63-4P	865849-64-5P	865849-65-6P
	865849-66-7P	865849-67-8P	865849-68-9P	865849-69-0P	865849-70-3P
	865849-71-4P	865849-72-5P	865849-73-6P	865849-74-7P	865849-75-8P
	865849-76-9P	865849-77-0P	865849-78-1P	865849-79-2P	865849-80-5P
	865849-81-6P	865849-82-7P	865849-83-8P	865849-84-9P	865849-85-0P
	865849-86-1P	865849-87-2P	865849-88-3P	865849-89-4P	865849-90-7P

865849-91-8P 865849-92-9P 865849-93-0P 865849-94-1P 865849-95-2P
865849-96-3P 865849-97-4P 865849-98-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 108-49-6, 2,6-Dimethylpiperazine 110-85-0, Piperazine, reactions
140-75-0, 4-Fluorobenzylamine 776-04-5, 2-Trifluoromethylbenzenesulfonyl chloride

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 865849-99-6P 865850-00-6P 865850-01-7P 865850-02-8P
865850-03-9P 865850-04-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)


IT 865849-99-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

RN 865849-99-6 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-benzoyl-N-[(4-fluorophenyl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



L41 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2005:612287 HCAPLUS

DN 143:133351

ED Entered STN: 15 Jul 2005

TI Preparation of pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors

IN Salom, Barbara; D'Anello, Matteo; Brasca, Maria Gabriella; Giordano, Patrizia; Martina, Katia; Brookfield, Frederick Arthur; Trigg, William John; Boyd, Edward Andrew; Larard, Jonathan Anthony; Tesei, Dania

PA Pharmacia Italia S.p.A., Italy

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C07D-0471/04

ICS A61K-0031/437; A61P-0035/00

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))

Section cross-reference(s): 1, 63

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO2005063747			2004WO-EP14676	20041223
W: AE, A			BB, BG, BR, BW, BY, BZ, CA, CH,	
CN, C			DZ, EC, EE, EG, ES, FI, GB, GD,	
GE, G			IS, JP, KE, KG, KP, KR, KZ, LC,	
LK, L			MG, MK, MN, MW, MX, MZ, NA, NI,	
NO, NL, OM, PG, PH, PL, PT, RO,			RU, SC, SD, SE, SG, SK, SL, SY,	
TJ, TM, TN, TR, TT, TZ, UA, UG,			US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW: BW, GH, GM, KE, LS, MW, MZ,			NA, SD, SL, SZ, TZ, UG, ZM, ZW,	
AZ, BY, KG, KZ, MD, RU, TJ, TM,			AT, BE, BG, CH, CY, CZ, DE, DK,	

EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
MR, NE, SN, TD, TG



US2005209269 A1 20050922 2004US-0020794 20041223
PRAI 2003GB-0030042 A 20031224

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2005063747	ICM	C07D-0471/04
	ICS	A61K-0031/437; A61P-0035/00
	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0035-00 [ICS,7]
	ECLA	C07D471/04+221B+209B
US2005209269	IPCI	A61K0031-4745 [ICM,7]; C07D0471-02 [ICS,7]
	NCL	514/300.000
	ECLA	C07D471/04+221B+209B

OS MARPAT 143:133351

GI



- AB The title compds. [I; R = Ra, CORa, CONRaRb, SO2Ra, CO2Ra; R1 = NRcRd, ORc; Ra, Rb, Rc and Rd = H, alkyl, cycloalkyl, etc.; R2 = alkyl, alkenyl, cycloalkyl, etc.] and pharmaceutically acceptable salts thereof together with pharmaceutical compns. comprising them, as well as combinatorial libraries of compds. I, are disclosed. Preparation of compds. I is described in ten examples. E.g., a multi-step synthesis of II, starting from 5-nitro-1H-pyrazolo[2,3-b]pyridine-3-carboxylic acid and 4-fluorobenzylamine-bearing resin, was given. The compds. I or compns. may be useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity (no biol. data given) such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune diseases and neurodegenerative disorders. Also disclosed is a process under SPS conditions for preparing the compds. I and chemical libraries comprising a plurality of them.
- ST pyrrolopyridine prepn protein kinase inhibitor antitumor antiproliferative antiviral; Alzheimer disease pyrrolopyridine prepn; neurodegenerative disorder pyrrolopyridine prepn; combinatorial library pyrrolopyridine prepn protein kinase inhibitor
- IT Sarcoma
(Kaposi's, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
- IT Antiarteriosclerotics

(antiatherosclerotics, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Prostate gland, disease
(benign hyperplasia, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hyperplasia
(benign prostatic, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, disease
(degeneration, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Lung, disease
(fibrosis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Thyroid gland, neoplasm
(follicle cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Chemotherapy
Radiotherapy
(for augmentation of; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Inflammation
Kidney, disease
(glomerulonephritis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Transplant and Transplantation
(host-vs.-graft reaction; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(lymphoid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(mesenchymal, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Neoplasm
(metastasis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Endocrine system, neoplasm
Neoplasm
(multiple endocrine neoplasia, treating familial adenomatosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Hematopoietic precursor cell
(myeloid, treating hematopoietic tumors of lymphoid or myeloid lineage; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Mesenchyme
(neoplasm, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Nervous system, neoplasm
(neurofibromatosis type 1, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Bone, neoplasm
Sarcoma
(osteosarcoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Digestive tract, neoplasm
(polyposis, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Angiogenesis
Angiogenesis inhibitors
Anti-Alzheimer's agents
Antitumor agents
Antiviral agents
Cell proliferation
Combinatorial chemistry
Combinatorial library

Human
 Immunomodulators
 Immunosuppressants
 Nervous system agents
 Transplant rejection
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Fibrosis
 (pulmonary, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Artery, disease
 (restenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Testis, neoplasm
 (seminoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Blood vessel
 (smooth muscle, treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Carcinoma
 (squamous cell, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Artery, disease
 (stenosis, treating post-surgical stenosis and restenosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Carcinoma
 (teratocarcinoma, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Alopecia
 (treating or preventing radiotherapy-induced or chemotherapy-induced alopecia; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Atherosclerosis
 (treating vascular smooth cell proliferation associated with atherosclerosis; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Alzheimer's disease
 Antiarthritics
 Arthritis
 Autoimmune disease
 Carcinoma
 Melanoma
 Nervous system, neoplasm
 Psoriasis
 (treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Infection
 (viral, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Skin, disease
 (xanthoma, treating keratoxanthoma; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT Skin, disease
 (xeroderma pigmentosum, treating; preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-95-1P 858340-96-2P 858340-97-3P 858340-98-4P 858340-99-5P
 RL: CPN (Combinatorial preparation); CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858339-48-7P 858339-49-8P 858339-50-1P 858339-51-2P
 858339-52-3P 858339-53-4P 858339-54-5P 858339-56-7P
 858339-57-8P 858339-58-9P 858339-59-0P
 858339-60-3P 858339-61-4P 858339-62-5P 858339-63-6P
 858339-64-7P 858339-65-8P 858339-66-9P 858339-67-0P
 858339-68-1P 858339-69-2P 858339-70-5P 858339-71-6P

858339-72-7P 858339-73-8P 858339-74-9P
 858339-75-0P 858339-76-1P 858339-77-2P 858339-78-3P
 858339-79-4P 858339-80-7P 858339-81-8P 858339-82-9P
 858339-83-0P 858339-84-1P 858339-85-2P 858339-86-3P
 858339-87-4P 858339-88-5P 858339-89-6P 858339-90-9P
 858339-91-0P 858339-92-1P 858339-93-2P 858339-94-3P
 858339-95-4P 858339-96-5P 858339-97-6P 858339-98-7P
 858339-99-8P 858340-00-8P 858340-01-9P 858340-02-0P
 858340-03-1P 858340-04-2P 858340-05-3P
 858340-06-4P 858340-07-5P 858340-08-6P 858340-09-7P
 858340-10-0P 858340-11-1P 858340-12-2P 858340-13-3P
 858340-14-4P 858340-15-5P 858340-16-6P
 858340-17-7P 858340-18-8P 858340-19-9P
 858340-20-2P 858340-21-3P 858340-22-4P 858340-23-5P
 858340-24-6P 858340-25-7P 858340-26-8P 858340-27-9P 858340-28-0P
 858340-29-1P 858340-30-4P 858340-31-5P 858340-32-6P 858340-33-7P
 858340-34-8P 858340-35-9P 858340-36-0P 858340-37-1P 858340-38-2P
 858340-39-3P 858340-40-6P 858340-41-7P 858340-42-8P 858340-43-9P
 858340-44-0P 858340-45-1P 858340-46-2P 858340-47-3P 858340-48-4P
 858340-49-5P 858340-50-8P 858340-51-9P 858340-52-0P 858340-53-1P
 858340-54-2P 858340-55-3P 858340-56-4P 858340-57-5P 858340-58-6P
 858340-59-7P 858340-60-0P 858340-61-1P 858340-62-2P 858340-63-3P
 858340-64-4P 858340-65-5P 858340-66-6P 858340-67-7P 858340-68-8P
 858340-69-9P 858340-70-2P 858340-71-3P 858340-72-4P 858340-73-5P
 858340-74-6P 858340-75-7P 858340-76-8P 858340-77-9P 858340-78-0P
 858340-79-1P 858340-80-4P 858340-81-5P 858340-82-6P 858340-83-7P
 858340-84-8P 858340-85-9P 858340-86-0P
 858340-87-1P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 98-09-9, Benzenesulfonyl chloride 98-88-4, Benzoyl chloride 110-89-4, Piperidine, reactions 111-36-4, Butyl isocyanate 121-60-8, 4-(Acetylamino)benzenesulfonyl chloride 140-75-0, 4-Fluorobenzylamine 1885-14-9, Phenyl chloroformate

RL: CRT (Combinatorial reactant); RCT (Reactant); CMBI (Combinatorial study); RACT (Reactant or reagent)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-93-9P 858340-94-0P

RL: CRT (Combinatorial reactant); RCT (Reactant); SPN (Synthetic preparation); CMBI (Combinatorial study); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 71-23-8, n-Propanol, reactions 34461-00-2, Sodium nitromalonalddehyde 245064-81-7 858341-00-1

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

IT 858340-88-2P 858340-89-3P 858340-90-6P 858340-91-7P 858340-92-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

(1) Graczyk, P; WO--03082868 A 2003 HCAPLUS

(2) Longo, A; WO---0198299 A 2001 HCAPLUS

IT 858339-48-7P 858339-49-8P 858339-52-3P

858339-53-4P 858339-57-8P 858339-58-9P

858339-59-0P 858339-60-3P 858339-65-8P

858339-66-9P 858339-69-2P 858339-70-5P

858339-73-8P 858339-74-9P 858339-75-0P

858339-76-1P 858339-81-8P 858339-82-9P

858339-85-2P 858339-86-3P 858339-89-6P

858339-90-9P 858339-91-0P 858339-92-1P

858339-96-5P 858339-97-6P 858340-00-8P


858340-01-9P 858340-04-2P 858340-05-3P

858340-06-4P 858340-07-5P 858340-12-2P
 858340-13-3P 858340-15-5P 858340-16-6P
 858340-17-7P 858340-18-8P 858340-19-9P
 858340-20-2P 858340-85-9P 858340-86-0P
 858340-87-1P

RL: CPN (Combinatorial preparation); PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); CMBI (Combinatorial study); PREP (Preparation); USES (Uses)
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)


RN 858339-48-7 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-49-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-52-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(3-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-53-4 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(3-methoxyphenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)




RN 858339-57-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-1-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-58-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-59-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-1-methyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858339-60-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-1-methyl-N-[(4-methylphenyl)methyl]- (9CI) (CA INDEX NAME)




RN 858339-65-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-66-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-69-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-70-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-73-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-74-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-75-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-methylphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-76-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetylamino)-N-[(4-methylphenyl)methyl]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-81-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-82-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-85-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-methyl-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-86-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-methyl-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-89-6 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-5-[(methylsulfonyl)amino]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-90-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-91-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[(methylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-92-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858339-96-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858339-97-6 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-00-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858340-01-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-04-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[(methylsulfonyl)amino]-N,1-bis(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858340-05-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-06-4 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-methylphenyl)methyl]-5-[(methylsulfonyl)amino]-1-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858340-07-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-methylphenyl)methyl]-1-(phenylmethyl)-5-[(phenylsulfonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-12-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-13-3 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-methyl-5-[[propylamino]carbonyl]- (9CI) (CA INDEX NAME)




RN 858340-15-5 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-(phenylmethyl)-5-[[propylamino]carbonyl]- (9CI) (CA INDEX NAME)




RN 858340-16-6 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-methyl-N-[(4-methylphenyl)methyl]-5-[[propylamino]carbonyl]- (9CI) (CA INDEX NAME)




RN 858340-17-7 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(4-fluorophenyl)methyl]-1-(phenylmethyl)-5-[[1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 858340-18-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N-[(3-methoxyphenyl)methyl]-1-(phenylmethyl)-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-19-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[(1-piperidinylcarbonyl)amino]- (9CI) (CA INDEX NAME)




RN 858340-20-2 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, N,1-bis(phenylmethyl)-5-[[(propylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 858340-85-9 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(acetamido)-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 858340-86-0 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[[[4-(acetylamino)phenyl]sulfonyl]amino]-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 858340-87-1 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-[[[butylamino]carbonyl]amino]-1-(1,1-dimethylethyl)-N-(phenylmethyl)- (9CI) (CA INDEX NAME)



=> d all fhitrstr 141 3-4

L41 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN

AN 2004:927204 HCAPLUS

DN 141:395538

ED Entered STN: 04 Nov 2004

TI Preparation of 7-azaindolyglyoxylamides as phosphodiesterase IV inhibitors.

IN Hoefgen, Norbert; Kuss, Hildegard; Olbrich, Matthias; Egerland, Ute; Rundfeldt, Chris; Steinike, Karin; Schindler, Rudolf

PA Elbion A.-G., Germany

SO PCT Int. Appl., 58 pp.

CODEN: PIXXD2

DT Patent

LA German

IC ICM C07D-0471/04

ICS A61K-0031/437; A61P-0035/00

CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))


Section cross-reference(s): 1, 63

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO2004094416	A1	20041104	2004WO-EP04339	20040423 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	DE--10318610	A1	20041111	2003DE-1018610	20030424 <--
	US2004224971	A1	20041111	2004US-0826136	20040416 <--
	CA---2523063	AA	20041104	2004CA-2523063	20040423 <--
	EP---1613627	A1	20060111	2004EP-0729102	20040423 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR			
PRAI	2003DE-1018610	A	20030424 <--		
	2004WO-EP04339	W	20040423		

CLASS


PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2004094416	ICM	C07D-0471/04
	ICS	A61K-0031/437; A61P-0035/00
	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0035-00 [ICS,7]
DE--10318610	ECLA	C07D471/04+221B+209B <--
	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0019-00 [ICS,7]; A61P0011-00 [ICS,7]; A61P0031-00 [ICS,7]; A61P0035-00 [ICS,7]
US2004224971	ECLA	C07D471/04+221B+209B <--
	IPCI	C07D0471-02 [ICM,7]; C07D0043-02 [ICS,7]; A61K0031-4745 [ICS,7]; A61K0031-4439 [ICS,7]
	NCL	514/300.000
CA---2523063	ECLA	C07D471/04+221B+209B <--
	IPCI	C07D0471-04 [ICM,7]; A61P0035-00 [ICS,7]; A61K0031-437 [ICS,7]
EP---1613627	ECLA	C07D471/04+221B+209B <--
	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61P0035-00 [ICS,7]
	ECLA	C07D471/04+221B+209B <--
OS	MARPAT 141:395538	
GI		



AB Title compds. [I; A = N, N-oxide group; B = C, N, N-oxide group; R1 = (substituted) alkyl, alkenyl; R2 = H, alkyl; R3, R4 = H, alkyl, OH, SH, NH2, NO2, cyano, SO3H, CO2H, alkoxy carbonyl, halo, alkoxy, alkylthio, (substituted) Ph, pyridyl, etc.], were prepared Thus, N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-azaindol-3-yl]glyoxylic acid

amide in CH₂Cl₂ was treated dropwise with m-chloroperbenzoic acid in HOAc followed by stirring for 7 days to give 9.4% N-(3,5-dichloropyridin-4-yl) [1-(4-fluorobenzyl)-7-oxo-7-azaindol-3-yl]glyoxylic acid amide. I inhibited phosphodiesterase 4 with IC₅₀'s in the range of 10⁻¹⁰ M to 10⁻⁵ M.

- ST azaindolylglyoxylamide prepn phosphodiesterase inhibitor;
hyperproliferation treatment azaindolylglyoxylamide prepn; eosinophil
neutrophil connected disease treatment pyridinyl azaindolylglyoxylamide
- IT Cell proliferation
(hyperproliferative disorder treatment; preparation of
azaindolylglyoxylamides as phosphodiesterase IV inhibitors)
- IT Drug delivery systems
Human
(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)
- IT Eosinophil
(treatment of diseases connected with eosinophils; preparation of
azaindolylglyoxylamides as phosphodiesterase IV inhibitors)
- IT Neutrophil
(treatment of diseases connected with neutrophils; preparation of
azaindolylglyoxylamides as phosphodiesterase IV inhibitors)
- IT 785815-36-3P 785815-37-4P 785815-38-5P
785815-39-6P 785815-40-9P 785815-41-0P
785815-42-1P 785815-43-2P 785815-44-3P
785815-45-4P 785815-46-5P 785815-47-6P
785815-48-7P 785815-49-8P 785815-50-1P
785815-51-2P 785815-52-3P 785815-53-4P
785815-54-5P 785815-55-6P 785815-56-7P
785815-57-8P 785815-58-9P 785815-59-0P
785815-60-3P 785815-61-4P 785815-62-5P
785815-63-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase
IV inhibitors)
- IT 9036-21-9, Phosphodiesterase IV
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; preparation of azaindolylglyoxylamides as phosphodiesterase IV
inhibitors)
- IT 418794-42-0 785815-64-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of azaindolylglyoxylamides as phosphodiesterase IV inhibitors)
- RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
- RE
(1) Asta Medica Ag; WO---9809946 A 1998 HCAPLUS
(2) Dresden, A; DE--19818964 A 1999 HCAPLUS
(3) Polymeropoulos, E; WO---0234747 A 2002 HCAPLUS
(4) Rahm; WO---9611929 A 1996 HCAPLUS
- IT 785815-36-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)
(claimed compound; preparation of azaindolylglyoxylamides as phosphodiesterase
IV inhibitors)
- RN 785815-36-3 HCAPLUS
- CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-
fluorophenyl)methyl]- α -oxo-, 7-oxide (9CI) (CA INDEX NAME)



L41 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2006 ACS on STN
 AN 2002:332190 HCAPLUS
 DN 136:340669
 ED Entered STN: 03 May 2002
 TI Novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors
 IN Hoefgen, Norbert; Egerland, Ute; Kronbach, Thomas;
 Marx, Degenhard; Szelenyi, Stefan; Kuss, Hildegard;
 Polymeropoulos, Emmanuel
 PA Arzneimittelwerk Dresden GmbH, Germany
 SO PCT Int. Appl., 55 pp.
 CODEN: PIXXD2
 DT Patent
 LA German
 IC ICM C07D-0471/04
 ICS A61P-0011/00; A61K-0031/40
 CC 28-2 (Heterocyclic Compounds (More Than One Hetero Atom))
 Section cross-reference(s): 1

FAN.CNT 1


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO2002034747	A1	20020502	2001WO-EP12376	20011025
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG DE--10053275 A1 20020502 2000DE-1053275 20001027 CA---2428468 AA 20020502 2001CA-2428468 20011025 AU2002021753 A5 20020506 2002AU-0021753 20011025 EP---1330455 A1 20030730 2001EP-0988718 20011025 EP---1330455 B1 20050803 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR EE-200300166 A 20030815 2003EE-0000166 20011025 BR2001014903 A 20031014 2001BR-0014903 20011025 JP2004512337 T2 20040422 2002JP-0537738 20011025 NZ----525369 A 20040924 2001NZ-0525369 20011025 AT----301121 E 20050815 2001AT-0988718 20011025 RU---2268887 C2 20060127 2003RU-0115621 20011025 NO2003001722 A 20030414 2003NO-0001722 20030414 BG----107725 A 20040831 2003BG-0107725 20030416 ZA2003003236 A 20030731 2003ZA-0003236 20030425 HR2003000427 A1 20030831 2003HR-0000427 20030526				

US2004106641	A1	20040603	2003US-0399051	20030617
PRAI 2000DE-1053275	A	20001027		
2000US-244342P	P	20001030		
2001WO-EP12376	W	20011025		

CLASS

PATENT NO.	CLASS	PATENT FAMILY CLASSIFICATION CODES
WO 2002034747	ICM	C07D-0471/04
	ICS	A61P-0011/00; A61K-0031/40
	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
	ECLA	C07D471/04+221B+209B
DE--10053275	IPCI	C07D0471-04 [ICM,7]; A61K0031-495 [ICS,7]; A61K0031-505 [ICS,7]
	ECLA	C07D471/04+221B+209B
CA---2428468	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
AU2002021753	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
EP---1330455	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
	ECLA	C07D471/04+221B+209B
EE-200300166	IPCI	A61K0031-40 [ICM,7]; A61P0011-00 [ICS,7]; C07D0471-04 [ICS,7]
BR2001014903	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
JP2004512337	IPCI	C07D0471-04 [ICM,7]; A61K0031-437 [ICS,7]; A61K0031-444 [ICS,7]; A61K0031-496 [ICS,7]; A61K0031-513 [ICS,7]; A61K0031-5377 [ICS,7]; A61K0031-541 [ICS,7]; A61P0001-04 [ICS,7]; A61P0003-10 [ICS,7]; A61P0005-48 [ICS,7]; A61P0007-12 [ICS,7]; A61P0009-10 [ICS,7]; A61P0011-00 [ICS,7]; A61P0011-02 [ICS,7]; A61P0011-06 [ICS,7]; A61P0013-00 [ICS,7]; A61P0013-04 [ICS,7]; A61P0013-08 [ICS,7]; A61P0013-12 [ICS,7]; A61P0015-10 [ICS,7]; A61P0017-00 [ICS,7]; A61P0017-06 [ICS,7]; A61P0019-02 [ICS,7]; A61P0019-08 [ICS,7]; A61P0019-10 [ICS,7]; A61P0025-16 [ICS,7]; A61P0025-18 [ICS,7]; A61P0025-28 [ICS,7]; A61P0025-30 [ICS,7]; A61P0027-14 [ICS,7]; A61P0029-00 [ICS,7]; A61P0031-04 [ICS,7]; A61P0031-12 [ICS,7]; A61P0031-18 [ICS,7]; A61P0033-00 [ICS,7]; A61P0033-02 [ICS,7]; A61P0037-02 [ICS,7]; A61P0037-06 [ICS,7]; A61P0037-08 [ICS,7]; A61P0039-02 [ICS,7]; A61P0043-00 [ICS,7]
	FTERM	4C065/AA04; 4C065/BB04; 4C065/CC01; 4C065/DD02; 4C065/EE02; 4C065/HH01; 4C065/JJ01; 4C065/KK01; 4C065/LL01; 4C065/PP12; 4C065/PP15; 4C065/PP16; 4C065/PP17; 4C065/QQ04; 4C086/AA01; 4C086/AA02; 4C086/AA03; 4C086/AA04; 4C086/BC17; 4C086/BC42; 4C086/BC50; 4C086/BC73; 4C086/BC88; 4C086/CB05; 4C086/MA01; 4C086/MA04; 4C086/NA14; 4C086/ZA01; 4C086/ZA12; 4C086/ZA15; 4C086/ZA16; 4C086/ZA33; 4C086/ZA34; 4C086/ZA45; 4C086/ZA59; 4C086/ZA60; 4C086/ZA66; 4C086/ZA68; 4C086/ZA81; 4C086/ZA84; 4C086/ZA89; 4C086/ZA96; 4C086/ZA97; 4C086/ZB07; 4C086/ZB08; 4C086/ZB11; 4C086/ZB13; 4C086/ZB15; 4C086/ZB33; 4C086/ZB35; 4C086/ZB37; 4C086/ZB38; 4C086/ZC02; 4C086/ZC20; 4C086/ZC35; 4C086/ZC37; 4C086/ZC55
NZ----525369	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
AT----301121	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40 [ICS,7]
	ECLA	C07D471/04+221B+209B
RU---2268887	IPCI	C07D0471-04 [I,A]; A61P0011-00 [I,A]; A61K0031-40 [I,A]
NO2003001722	IPCI	C07D0471-04 [ICM,7]
BG----107725	IPCI	C07D0471-04 [ICM,7]; A61P0011-00 [ICS,7]; A61K0031-40

[ICS, 7]
 ZA2003003236 IPCI C07D [ICM, 7]; A61P [ICS, 7]; A61K [ICS, 7]
 HR2003000427 IPCI C07D0471-04 [ICM, 7]; A61P0011-00 [ICS, 7]; A61K0031-40
 [ICS, 7]
 US2004106641 IPCI A61K0031-4745 [ICM, 7]
 NCL 514/300.000
 ECLA C07D471/04+221B+209B
 OS CASREACT 136:340669; MARPAT 136:340669
 GI



AB 7-Azaindoles I [n = 1, 2; R1 = (un)substituted alkyl, alkenyl; R2, R3 = H, (un)substituted alkyl, Ph, pyridyl, uracilyl, triazolyl; NR2R3 = morpholino, thiomorpholino, thiomorpholine S,S-dioxide, 4-methylpiperazino] were prepared for use as PDE-4 inhibitors. Thus, 1-cyclopropylmethyl-7-azaindole-3-carboxylic acid was converted to the acid chloride and treated with 4-aminomethylpyridine to give the amide which had an IC50 for PDE-4 inhibition of 0.710 $\mu\text{mol./L}$.

ST azaindolescarboxamide prepn phosphodiesterase inhibitor

IT Eosinophil
 Neutrophil
 (preparation of novel 7-azaindolescarboxamides as phosphodiesterase 4 inhibitors)

IT Tumor necrosis factors
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (preparation of novel 7-azaindolescarboxamides as phosphodiesterase 4 inhibitors)

IT 9036-21-9
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (IV; preparation of novel 7-azaindolescarboxamides as phosphodiesterase 4 inhibitors)

IT 418794-16-8P 418794-19-1P 418794-38-4P
 418794-40-8P 418794-42-0P 418794-44-2P
 418794-46-4P 418794-47-5P 418794-49-7P
 418794-55-5P 418794-57-7P 418794-59-9P
 418794-61-3P 418794-63-5P 418794-64-6P
 418794-66-8P 418794-73-7P 418794-82-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of novel 7-azaindolescarboxamides as phosphodiesterase 4 inhibitors)

IT 61-82-5, 1H-1,2,4-Triazol-3-amine 94-09-7, Ethyl 4-aminobenzoate
 109-01-3, N-Methylpiperazine 110-91-8, Morpholine, reactions 111-95-5
 150-13-0, 4-Aminobenzoic acid 608-31-1, 2,6-Dichloroaniline 1003-40-3,
 4-Aminopyridine hydrochloride 3731-53-1, 4-Aminomethylpyridine
 6270-46-8, 5-Amino-6-methyluracil 6315-89-5, 3,4-Dimethoxyaniline
 35965-29-8 35965-33-4 39093-93-1, Thiomorpholine S,S-dioxide
 55276-24-9, 5-Amino-1,3,6-trimethyluracil 142648-55-3 418794-90-8,
 1-(Cyclopropylmethyl)-7-azaindole-3-carboxylic acid 418794-93-1,
 1-Isobutyl-7-azaindole-3-carboxylic acid 418794-94-2,
 1-Hexyl-7-azaindole-3-carboxylic acid 418794-96-4 418794-98-6
 418795-00-3 418795-02-5 418795-04-7, 4-Aminomethyl-3,5-dichloropyridine
 418795-06-9 418795-10-5 418795-13-8 418795-15-0
 418795-17-2 418795-19-4 418795-20-7 418795-22-9 418795-24-1
 418795-26-3 418795-27-4 418795-29-6 418795-30-9 418795-32-1

RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 418794-92-0P 418795-08-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

IT 418794-22-6P 418794-24-8P 418794-25-9P 418794-27-1P
418794-29-3P 418794-30-6P 418794-32-8P 418794-34-0P 418794-36-2P
418794-51-1P 418794-53-3P 418794-54-4P
418794-68-0P 418794-70-4P 418794-71-5P
418794-75-9P 418794-76-0P 418794-78-2P 418794-80-6P
418794-84-0P 418794-86-2P 418794-88-4P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Fujisawa Pharmaceut Co Ltd; JP--10120681 A 1998 HCAPLUS
- (2) Mouaddib, A; SYNTHESIS 2000, 4, P549 HCAPLUS
- (3) Smithkline Beecham Plc; WO---9611929 A 1996 HCAPLUS
- (4) Sterling Drug Inc; GB---1141949 A 1969 HCAPLUS

IT 418794-16-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RN 418794-16-8 HCAPLUS

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-(cyclopropylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



=> b uspatall

FILE 'USPATFULL' ENTERED AT 13:10:30 ON 31 JAN 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 13:10:30 ON 31 JAN 2006

CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> d bib abs fhitstr hitrn 140 tot

L40 ANSWER 1 OF 4 USPATFULL on STN

AN 2005:293602 USPATFULL

TI Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process

for their preparation and pharmaceutical compositions comprising them

IN Salom, Barbara, Vedano al Lambro (MI), ITALY
 D'Anello, Matteo, Novate Milanese (MI), ITALY
 Brasca, Maria Gabriella, Milano, ITALY
 Giordano, Patrizia, Cuneo, ITALY
 Martina, Katia, Novara, ITALY
 Angelucci, Francesco, Milano, ITALY
 Brookfield, Frederick Arthur, Wallingford, UNITED KINGDOM
 Trigg, William John, Abingdon, UNITED KINGDOM
 Boyd, Edward Andrew, Reading, UNITED KINGDOM
 Larard, Jonathan Anthony, Pocklington, UNITED KINGDOM


PA Pharmacia Italia S.p.A., Milano, ITALY (non-U.S. corporation)
 PI US2005256151 A1 20051117
 AI 2004US-0020793 A1 20041223 (11)
 PRAI 2003GB-0030043 20031224
 DT Utility
 FS APPLICATION
 LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300,
 GARDEN CITY, NY, 11530, US
 CLMN Number of Claims: 24
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 5529
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compounds which are pyrrolo[2,3-b]pyridine derivatives or
 pharmaceutically acceptable salts thereof, their preparation process and
 pharmaceutical compositions comprising them are disclosed; these
 compounds are useful in the treatment of diseases caused by and/or
 associated with an altered protein kinase activity such as cancer, cell
 proliferative disorders, Alzheimer's disease, viral infections,
 auto-immune diseases and neurodegenerative disorders; also disclosed is
 a process under SPS conditions for preparing the compounds of the
 invention and chemical libraries comprising a plurality of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 865849-99-6P
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

RN 865849-99-6 USPATFULL
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-benzoyl-N-[(4-
 fluorophenyl)methyl]-5-nitro- (9CI) (CA INDEX NAME)



IT 865849-99-6P
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)


L40 ANSWER 2 OF 4 USPATFULL on STN
 AN 2005:241264 USPATFULL
 TI Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process
 for their preparation and pharmaceutical compositions comprising them

IN Salom, Barbara, Vedano al Lambro (MI), ITALY
 D'Anello, Matteo, Novate Milanese (MI), ITALY
 Brasca, Maria Gabriella, Milano, ITALY
 Giordano, Patrizia, Cuneo, ITALY
 Martina, Katia, Novara, ITALY
 Tesel, Dania, Ancona, ITALY

Brookfield, Frederick Arthur, Wallingford, UNITED KINGDOM
 Trigg, William John, Abingdon, UNITED KINGDOM
 Boyd, Edward Andrew, Reading, UNITED KINGDOM
 Larard, Jonathan Anthony, Pocklington, UNITED KINGDOM
 PA Pharmacia Italia S.p.A., Milano, ITALY (non-U.S. corporation)
 PI US2005209269 A1 20050922
 AI 2004US-0020794 A1 20041223 (11)
 PRAI 2003GB-0030042 20031224
 DT Utility
 FS APPLICATION
 LREP SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300,
 GARDEN CITY, NY, 11530, US
 CLMN Number of Claims: 31
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 2221
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Compounds which are pyrrolo[2,3-b]pyridine derivatives or
 pharmaceutically acceptable salts thereof, their preparation process and
 pharmaceutical compositions comprising them are disclosed; these
 compounds are useful in the treatment of diseases caused by and/or
 associated with an altered protein kinase activity such as cancer, cell
 proliferative disorders, Alzheimer's disease, viral infections,
 auto-immune diseases and neurodegenerative disorders; also disclosed is
 a process under SPS conditions for preparing the compounds of the
 invention and chemical libraries comprising a plurality of them.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 858339-48-7P
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)
 RN 858339-48-7 USPATFULL
 CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 5-(benzoylamino)-N-[(4-
 fluorophenyl)methyl]-1-methyl- (9CI) (CA INDEX NAME)



IT 858339-48-7P 858339-49-8P 858339-52-3P
 858339-53-4P 858339-57-8P 858339-58-9P
 858339-59-0P 858339-60-3P 858339-65-8P
 858339-66-9P 858339-69-2P 858339-70-5P
 858339-73-8P 858339-74-9P 858339-75-0P
 858339-76-1P 858339-81-8P 858339-82-9P
 858339-85-2P 858339-86-3P 858339-89-6P
 858339-90-9P 858339-91-0P 858339-92-1P
 858339-96-5P 858339-97-6P 858340-00-8P
 858340-01-9P 858340-04-2P 858340-05-3P
 858340-06-4P 858340-07-5P 858340-12-2P
 858340-13-3P 858340-15-5P 858340-16-6P
 858340-17-7P 858340-18-8P 858340-19-9P
 858340-20-2P 858340-85-9P 858340-86-0P
 858340-87-1P
 (preparation of pyrrolo[2,3-b]pyridine derivs. as kinase inhibitors)

L40 ANSWER 3 OF 4 USPATFULL on STN
 AN 2004:286803 USPATFULL
 TI 7-azaindoles and the use thereof as therapeutic agents
 IN Hofgen, Nobert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF
 Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF

Olbrich, Matthias, Moritzburg, GERMANY, FEDERAL REPUBLIC OF
 Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF
 Rundfeldt, Chris, Coswig, GERMANY, FEDERAL REPUBLIC OF
 Steinike, Karin, Radebul, GERMANY, FEDERAL REPUBLIC OF
 Schindler, Rudolf, Dresden, GERMANY, FEDERAL REPUBLIC OF


PI US2004224971 A1 20041111
 AI 2004US-0826136 A1 20040416 (10)
 PRAI DE 2003-10318610 20030424
 DT Utility
 FS APPLICATION
 LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
 CLMN Number of Claims: 21
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1093

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to substituted 7-azaindoles, process for their preparation, pharmaceutical preparations which comprise these compounds, and the pharmaceutical use of these compounds, which are inhibitors of phosphodiesterase 4, as active ingredients for the treatment of disorders which can be influenced by inhibition of phosphodiesterase 4 activity in particular in immunocompetent cells (e.g. macrophages and lymphocytes) by the compounds of the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 785815-36-3P
 (claimed compound; preparation of azaindolyglyoxylamides as phosphodiesterase IV inhibitors)
 RN 785815-36-3 USPATFULL
 CN 1H-Pyrrolo[2,3-b]pyridine-3-acetamide, N-(3,5-dichloro-4-pyridinyl)-1-[(4-fluorophenyl)methyl]- α -oxo-, 7-oxide (9CI) (CA INDEX NAME)



IT 785815-36-3P 785815-37-4P 785815-38-5P
 785815-39-6P 785815-40-9P 785815-41-0P
 785815-42-1P 785815-43-2P 785815-44-3P
 785815-45-4P 785815-46-5P 785815-47-6P
 785815-48-7P 785815-49-8P 785815-50-1P
 785815-51-2P 785815-52-3P 785815-53-4P
 785815-54-5P 785815-55-6P 785815-56-7P
 785815-57-8P 785815-58-9P 785815-59-0P
 785815-60-3P 785815-61-4P 785815-62-5P
 785815-63-6P
 (claimed compound; preparation of azaindolyglyoxylamides as phosphodiesterase IV inhibitors)
 IT 418794-42-0 785815-64-7
 (preparation of azaindolyglyoxylamides as phosphodiesterase IV inhibitors)

L40 ANSWER 4 OF 4 USPATFULL on STN

AN 2004:139465 USPATFULL
 TI Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same
 IN Hofgen, Norbert, Ottendorf-Okrilla, GERMANY, FEDERAL REPUBLIC OF
 Egerland, Ute, Radebeul, GERMANY, FEDERAL REPUBLIC OF
 Kronbach, Thomas, Radebeul, GERMANY, FEDERAL REPUBLIC OF
 Marx, Degenhard, Radolfzell, GERMANY, FEDERAL REPUBLIC OF
 Szelenyi, Stefan, Schwaig, GERMANY, FEDERAL REPUBLIC OF
 Kuss, Hildegard, Dresden, GERMANY, FEDERAL REPUBLIC OF
 Polymeropoulos, Emmanuel, Frankfurt, GERMANY, FEDERAL REPUBLIC OF
 PI US2004106641 A1 20040603
 AI 2003US-0399051 A1 20030617 (10)
 2001WO-EP12376 20011025
 PRAI DE 2000-10053275 20001027
 DT Utility
 FS APPLICATION
 LREP FULBRIGHT & JAWORSKI, LLP, 666 FIFTH AVE, NEW YORK, NY, 10103-3198
 CLMN Number of Claims: 18
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1214

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB The invention relates to new 7-azaindoles, their use as inhibitors of phosphodiesterase 4 and to methods for their synthesis.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 418794-16-8P
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

RN 418794-16-8 USPATFULL

CN 1H-Pyrrolo[2,3-b]pyridine-3-carboxamide, 1-(cyclopropylmethyl)-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)



IT 418794-16-8P 418794-38-4P 418794-40-8P
 418794-42-0P 418794-44-2P 418794-46-4P
 418794-47-5P 418794-49-7P 418794-55-5P
 418794-57-7P 418794-59-9P 418794-61-3P
 418794-63-5P 418794-64-6P 418794-66-8P
 418794-73-7P 418794-82-8P
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)
 IT 418794-25-9P 418794-51-1P 418794-53-3P
 418794-54-4P 418794-68-0P 418794-70-4P
 418794-71-5P 418794-84-0P 418794-86-2P
 (preparation of novel 7-azaindolecarboxamides as phosphodiesterase 4 inhibitors)

=> d his

(FILE 'HOME' ENTERED AT 11:57:09 ON 31 JAN 2006)

FILE 'HCAPLUS' ENTERED AT 11:57:19 ON 31 JAN 2006

L1 1 US2004224971/PN OR (US2004-826136# OR DE2003-10318610#)/AP, PRN
E HOFGEN N/AU
L2 12 E3-4
E HOEFGEN N/AU
L3 31 E3-4
E KUSS H/AU
L4 51 E3-6, E11
E OLBRICH M/AU
L5 24 E3-4, E7
E EGERLAND U/AU
L6 20 E3-4
E RUNDFELDT C/AU
L7 71 E3-4
E STEINKE K/AU
E STEINKE K/AU
L8 6 E3-4
E SCHINDLER R/AU
L9 775 E3-11
E SCHINDLER RUD/AU
L10 28 E4-7
L11 17 ELBION/CS, PA
E ELBION/CS, PA
L12 17 E3-14

FILE 'REGISTRY' ENTERED AT 12:06:35 ON 31 JAN 2006

FILE 'HCAPLUS' ENTERED AT 12:07:37 ON 31 JAN 2006

L13 TRA L1 1- RN : 31 TERMS

FILE 'REGISTRY' ENTERED AT 12:07:38 ON 31 JAN 2006

L14 31 SEA L13
L15 STR
L16 2 L15
L17 52 L15 FULL
SAV TEM BAL136F0/A L17
L18 30 L17 AND L14

FILE 'HCAPLUS' ENTERED AT 12:27:13 ON 31 JAN 2006

L19 2 L17
L20 2 L1-12 AND L19

FILE 'USPATFULL, USPAT2' ENTERED AT 12:31:30 ON 31 JAN 2006

L21 2 L17
E HOEFGEN N/AU
E HOFGEN N/AU

FILE 'HCAOLD' ENTERED AT 12:33:43 ON 31 JAN 2006

L22 0 L17

FILE 'REGISTRY' ENTERED AT 12:46:26 ON 31 JAN 2006

L23 STR L15
L24 0 L23
L25 98 L23 FULL
L26 46 L25 NOT L17
L27 30 L25 AND L14

FILE 'HCAPLUS' ENTERED AT 12:55:05 ON 31 JAN 2006

L28 3 L26
L29 1 L28 AND L1-12
L30 4 L19, L28 AND L1-12, L19-20, L28-29

FILE 'USPATFULL, USPAT2' ENTERED AT 12:58:53 ON 31 JAN 2006
L31 3 L26
L32 4 L21,L31

FILE 'HCAOLD' ENTERED AT 12:59:35 ON 31 JAN 2006
L33 0 L26

FILE 'REGISTRY' ENTERED AT 13:00:51 ON 31 JAN 2006
L34 STR L23
L35 1 L34
L36 101 L34 FULL
L37 3 L36 NOT L25

FILE 'HCAPLUS' ENTERED AT 13:05:47 ON 31 JAN 2006
L38 1 L37

FILE 'USPATFULL, USPAT2' ENTERED AT 13:06:16 ON 31 JAN 2006
L39 1 L37
L40 4 L32,L39

FILE 'HCAPLUS' ENTERED AT 13:07:15 ON 31 JAN 2006
L41 4 L30,L38

FILE 'HCAOLD' ENTERED AT 13:07:34 ON 31 JAN 2006
L42 0 L37

=>